Laidlaw Wealth Management LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 77 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Laidlaw Wealth Management LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$264,000
-25.2%
104,841
-15.3%
0.07%
-25.3%
Q2 2021$353,000
+29.8%
123,730
+6.9%
0.09%
-2.2%
Q1 2021$272,000
-9.3%
115,730
-32.2%
0.09%
+47.6%
Q4 2020$300,000
+141.9%
170,658
+28.6%
0.06%
+14.5%
Q3 2020$124,000
+19.2%
132,668
+10.9%
0.06%
+1.9%
Q2 2020$104,000
+16.9%
119,629
+11.4%
0.05%
-6.9%
Q1 2020$89,000
+229.6%
107,379
+259.7%
0.06%
+241.2%
Q4 2019$27,00029,8530.02%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders